Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of new myeloma agents on the transfusion laboratory.

Pathology - 1 Apr 2021

Jones Andrew D, Moayeri Morvarid, Nambiar Ashok

Abstract excerpt

Monoclonal antibody (mAb) therapy targeting CD38 and CD47 antigens expressed on cancer cells has transformed therapy options for patients with multiple myeloma as well as other haematological and non-haematological malignancies. While the on target effects of these new drugs highlight the promise of precision cancer therapeutics, the unintended, off target binding of drugs to red blood cells (RBCs) and platelets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ABO Blood-Group System
Share to ADP-ribosyl Cyclase 1
Share to Blood Grouping and Crossmatching

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Blood Platelets

Share to Blood Transfusion

Share to Laboratories

Share to Liquid Biopsy

Share to Multiple Myeloma

Source

Identifiers

PMID: 33707006
DOI: 10.1016/j.pathol.2021.01.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of new myeloma agents on the transfusion laboratory.PMID 33707006Read ↗

Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.Semantic proximity Read ↗

Spherotech-EDTA combined serum treatment reduces background more effectively as compared to One Lambda Adsorb Out™ and LIFECODES Serum Cleaner in Luminex-based solid-phase immunoassays for HLA antibody detection.Semantic proximity Read ↗

The impact of Daratumumab on transfusion service costsSemantic proximity Read ↗

Practical Management of Adverse Events Associated with Bispecific Antibodies for the Treatment of Multiple Myeloma: A Qualitative Interview StudySemantic proximity Read ↗

Review: monoclonal reagents and detection of unusual or rare phenotypes or antibodies.Semantic proximity Read ↗

Microfluidic Isolation of Aptamers with Affinity towards Multiple Myeloma Monoclonal Immunoglobulins (M-Ig)Semantic proximity Read ↗

Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.Semantic proximity Read ↗

Implementation of a molecular genotyping protocol for patients with warm autoantibodies.Semantic proximity Read ↗

Rare ABO Discrepancy in Multiple Myeloma: An Immunohematologic Challenge with Critical Transfusion Implications : Case reportSemantic proximity Read ↗

Paraprotein interferences: Insights from a short study involving multiple platforms and multiple measurands.Semantic proximity Read ↗

HLA antibody affinity determination: From HLA-specific monoclonal antibodies to donor HLA specific antibodies (DSA) in patient serum.Semantic proximity Read ↗

Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.